Study Suggest Opioids Should Not Be First Line Therapy for Chronic Non-Cancer Pain

PainRelief.com Interview with:

Dr. Jason Busse PhD Associate Professor McMaster University

Dr. Busse


Dr. Jason Busse PhD
Associate Professor
McMaster University

PainRelief.com: What is the background for this study?  

Response: The United States prescribes more opioids per capita than any other country in the world, and opioids are associated with addiction, overdose, and death. Many individuals living with chronic noncancer pain are managed with opioid therapy; however, we have limited knowledge regarding benefits and harms. We conducted a systematic review and meta-analysis to synthesize the evidence from all RCTs that explored an opioid vs. a non-opioid comparator for patients with chronic noncancer pain, and followed participants for at least 1 month. Continue reading

Three Genes Linked To Chronic Back Pain

PainRelief.com Interview with:
"Back Pain" by betterhealthosteopathy is licensed under CC PDM 3.0cDr. Frances MK Williams PhD

Department of Twin Research and Genetic Epidemiology
Division of Genetics & Molecular Medicine
Reader, King’s College London
Honorary Consultant in Rheumatology
Guy’s and St Thomas’ NHS Foundation Trust

PainRelief.com: What is the background for this study?

Response: This study was led by scientists at King’s College London and the University of Washington. It has identified three new genes associated with the development of chronic back pain.

The findings, which are published in PLOS Genetics, could pave the way for the creation of more effective treatments for the condition, the leading cause of disability worldwide.

Part funded by the European Union, the research project focussed on understanding why in most people an episode of back pain gets better, while in around 20% of people it can persist for many months – chronic back pain is defined as pain that persists for more than three months.

To better understand the origins of the chronic condition, researchers conducted a genome-wide association meta-analysis (GWAS) of chronic back pain studies comprising a total of 440,000 individuals. The average age of the study’s participants ranged from 50 to 76 years, and the genders were approximately balanced.  Continue reading